1. Scrip
  2. >>Business
  3. >>Strategy

Lilly's Web-Based Research Marketplace

 
• By Jeff Dvorin

Eli Lilly & Co. is venturing into previously uncharted e-R&D waters with Innocentive LLC, a wholly owned subsidiary launched earlier this summer with an undisclosed amount of backing. Innocentive offers a means for pharmaceutical and other research-dependent companies to farm out research problems to scientists who receive cash awards of up to $100,000 from any company that accepts a particular solution.

Eli Lilly & Co. is venturing into previously uncharted e-R&D waters with InnoCentive LLC , a wholly owned subsidiary launched earlier this summer with an undisclosed amount of backing from Lilly's e.Lilly Venture Fund. (See "Lilly's E-Venture Fund: Getting In At The Bottom," START-UP, February 2001 [A#2001900027.) InnoCentive offers a web-based means for pharmaceutical, biotech, and other research-dependent companies to farm out research problems to scientists who receive cash awards of up to $100,000 from any company that accepts a particular solution.

The InnoCentive marketplace consists of a web site featuring projects for which the posting companies are seeking scientific assistance. There are presently 31 such problems posted in the site, all...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Sun On Leqselvi US Launch Ahead, MFN Pricing And Pipeline Changes

 
• By Anju Ghangurde

Sun readies US debut of Leqselvi for alopecia areata, while PD-L1 inhibitor Unloxcyt is in the line up once the Checkpoint Therapeutics deal is completed. Management also discusses limited clarity on President Trump’s most favored nation pricing push, pipeline tweaks and M&A outlook.

Lilly To Diversify Pain Pipeline With SiteOne Acquisition

 
• By Joseph Haas

Deal snapshot: With several internal non-opioid pain candidates in Phase II or earlier, Lilly looks to add R&D potential in pain with $1bn buyout of SiteOne.

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

GlycoEra’s Series B Cash Will Fund Efforts To Take On FcRn Inhibitor Class

 
• By Joseph Haas

GlycoEra unveiled a $130m series B financing, saying the proceeds would enable it to take its first clinical candidate through proof-of-concept in autoimmune diseases.

More from Business

Sweden’s Hansa Slims Down Ahead of Key Readouts

 
• By Kevin Grogan

New CEO Renée Aguiar-Lucander is marking her mark.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Novo Nordisk’s CEO forced out; quantifying biopharma’s contribution to the US economy; a history of MASH deals; lift for AstraZeneca’s asthma ambitions; and major Japanese firms see US revenue growth.

Gilead Ready To Go After Hepatitis D Again

 
• By Joseph Haas

Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.